GLIPIQ vs Ozempic: Comparison Guide

GLIPIQ vs Ozempic: Comparison Guide

When people compare GLIPIQ and Ozempic, the main question is usually whether they are functionally different medicines or two brands built around the same drug. In practice, the most important point is that both are discussed in relation to semaglutide.

This guide gives you a simple, practical comparison so you can speak with your doctor more confidently. Consult your healthcare provider before starting any medication.

The shared active ingredient: semaglutide

Semaglutide belongs to the GLP-1 receptor agonist class. It helps regulate blood sugar, slows stomach emptying, and can reduce appetite. That is why semaglutide is discussed in both diabetes care and weight-management conversations.

Because GLIPIQ and Ozempic are both semaglutide-based, they are expected to work through the same core mechanism.

What is GLIPIQ?

GLIPIQ is a semaglutide brand launched in India by Glenmark Pharmaceuticals on March 21, 2026, for type 2 diabetes. It was approved by CDSCO after a Phase III study in Indian patients with type 2 diabetes. The company positioned it as an India-market semaglutide option intended to improve access and affordability.

What is Ozempic?

Ozempic is Novo Nordisk’s brand for semaglutide and is the best-known originator brand in this category. In India it was launched in December 2025 and is marketed for type 2 diabetes. It is widely recognized internationally and is backed by the major semaglutide clinical evidence base commonly referenced by clinicians.

Key differences: GLIPIQ vs Ozempic

1. Manufacturer

• GLIPIQ is associated with Glenmark Pharmaceuticals in India.
• Ozempic is made by Novo Nordisk.

2. Local-market positioning

Ozempic is the established originator brand. GLIPIQ is part of the newer semaglutide rollout in India, which may make the comparison more about access, pricing, and local availability than about a different underlying drug.

3. Device and packaging context

GLIPIQ comes as vials (used with dose-specific syringes) and as pre-filled pens, while Ozempic comes as a pre-filled FlexTouch pen. If you are given vials, you will need to draw up each dose yourself, so ask your doctor or pharmacist to show you how. Those practical details matter even when the active ingredient is the same.

4. Evidence context

The large semaglutide trials most clinicians cite are generally connected to the originator semaglutide evidence base. That evidence still informs discussions about GLIPIQ because the active ingredient remains semaglutide.

Side effects and safety

Since the core drug is semaglutide, the expected side-effect profile is broadly similar. Common side effects can include:

• nausea
• vomiting
• diarrhoea
• constipation
• abdominal discomfort
• appetite reduction

These effects often improve over time, especially when dose increases are gradual.

Both share the same semaglutide warnings. Seek urgent medical help for severe stomach pain that does not go away (it may spread to your back), signs of a serious allergic reaction, or being unable to keep fluids down. Low blood sugar is more likely if you also take insulin or a sulfonylurea, and people with diabetic eye disease should report any vision changes. Semaglutide is not used in pregnancy.

Questions worth asking your doctor

If you are deciding between GLIPIQ and Ozempic, ask:

• which brand is more available where you live
• what pen or delivery format you will be using
• how the price compares at your pharmacy
• what side effects are most common at your starting dose
• how often you should follow up after beginning treatment

Bottom line

GLIPIQ and Ozempic are best understood as semaglutide-based brands, not as different medication classes. The most important distinction is manufacturer and market context—Glenmark for GLIPIQ in India and Novo Nordisk for Ozempic—while the core drug mechanism remains the same.

Your doctor can help you compare cost, availability, and dosing in a way that fits your situation. Consult your healthcare provider before starting any medication.

Sources

• https://glenmarkpharma.com/gpl_pdfs/media/PR_Glenmark%20Pharmaceuticals%20launches%20GLIPIQ%E2%93%87.pdf
• https://www.novo-pi.com/ozempic.pdf
• https://www.storyboard18.com/brand-marketing/novo-nordisk-launches-ozempic-in-india-for-type-2-diabetes-aligns-pricing-with-wegovy-85831.htm
• https://cdsco.gov.in/opencms/opencms/en/Home/
• https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1